Praxsyn Corp (OTC:PXYN)

PALO ALTO, CA, March 12, 2014 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that revised February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues, excluding allowances for returns and discounts, exceeding $7.4 Million Dollars.  Prescription orders for transdermal topical pain medications continue to rise.

Additionally, the Company has paid in full the only short-term convertible note that was negotiated with Asher Enterprises, Inc. in 2013. The Company has settled all of its outstanding 14% Convertible Debentures and intends to settle all remaining 8% Debentures in the very near future.

In other news, the Company anticipates bringing on a new line of business in the form of genetic testing. The Company anticipates significant revenues from this new and exciting line of business if negotiations can be concluded successfully. The Company will update shareholders as events warrant.

Finally, work continues on the upcoming name change to Praxsyn Corporation. The Company expects to complete the process in the very near future.

IRVINE, CA, Feb. 26, 2014 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars.  "We are currently filling prescriptions for transdermal topical pain medications of approximately $400,000 dollars per day".  Stated Andrew Do, Mesa's President and Registered Pharmacist.

As controlled narcotic medications become more problematic and laws continue to limit options for physicians to control pain, other alternatives are being considered. Mesa's non-narcotic trans-dermal formulations for pain management are becoming more popular for managing pain suffered by injured workers.  Mesa is continuing its plan to increase staff for the surge in orders that has occurred as a result of its recent agreement with Trestles Pain Specialists LLC.